Sotagliflozin: a dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus

Aims To evaluate the evidence for the novel dual sodium‐glucose co‐transporter‐1 (SGLT1) and ‐2 (SGLT2) inhibitor, sotagliflozin, which may enhance the efficacy of SGLT2 inhibitors by additionally reducing intestinal glucose absorption. Methods The search terms ‘sotagliflozin’, ‘LX4211’, ‘SGLT’ and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetic medicine 2018-08, Vol.35 (8), p.1037-1048
Hauptverfasser:	Sims, H., Smith, K. H., Bramlage, P., Minguet, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Appetite Blood Glucose - drug effects Blood Glucose - metabolism Clinical trials Decision making Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diarrhea Glucose Glucose transporter Glycosides - therapeutic use Humans Hypoglycemic Agents - therapeutic use Insulin Intestine Ketoacidosis Pharmacodynamics Pharmacokinetics Safety Sodium Sodium-Glucose Transporter 1 - antagonists & inhibitors Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!